PHP
BIIB icon

Parkman Healthcare Partners’s Biogen BIIB Stock Holding History

Parkman Healthcare Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,425
Closed -$6.23M – 94
2025
Q4 		$6.23M Sell
35,425
-94,740
-73% -$15.5M 0.59% 52
2025
Q3 		$18.2M Buy
+130,165
New +$17.6M 1.9% 16
2023
Q2 		– Sell
-17,920
Closed -$4.98M – 97
2023
Q1 		$4.98M Buy
17,920
+2,703
+18% +$748K 1.08% 37
2022
Q4 		$4.21M Buy
+15,217
New +$4.3M 1.12% 37

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parkman Healthcare Partners's BIIB Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Biogen (BIIB) in Q1 2026, closing a stake of 35,425 shares — an estimated $6.23M sold.

Parkman Healthcare Partners first reported a position in BIIB in Q4 2022 and held it in 4 quarters. The position peaked at $18.2M in Q3 2025. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Parkman Healthcare Partners reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 35,425 Biogen shares in Q1 2026, an estimated $6.23M.
  • Parkman Healthcare Partners first reported a position in Biogen in Q4 2022 and held it in 4 quarters.
  • Parkman Healthcare Partners's Biogen position peaked at $18.2M in Q3 2025.
  • 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.